Skip to content

Integrative multi-omics and machine learning identify the SPI1-METTL16-PLIN4 axis as a candidate driver of steatosis in HepG2 cells.

Aug 2026 · Biochemical and Biophysical Research Communications - BBRC · Vol 834, pp. 154435 · 0 citations · 63 references
Medicine

TL;DR

The SPI1/METTL16/PLIN4 axis is identified as a potential regulatory mechanism contributing to in vitro steatosis, inflammation, and oxidative stress in steatotic HepG2 cells.

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with limited therapeutic options. This study aimed to identify potential regulators and explore their functional roles in a cellular model of NAFLD.

Methods

WGCNA was performed on the hepatic transcriptomic dataset GSE126848 (31 NAFLD vs. 26 controls), followed by integration with serum proteomic data from 12 NAFLD patients and 12 healthy controls. Hub genes were prioritized using three machine learning algorithms. Functional validation was conducted in a HepG2 cellular steatosis model induced by high fructose (3.2 g/L) and oleic acid (400 μM) for 48 h. Lipid accumulation was assessed by Oil Red O staining and triglyceride/total cholesterol measurement. Inflammation was evaluated by TNF-α and IL-6 secretion (ELISA), and oxidative stress by ROS levels (flow cytometry). The binding interaction between METTL16 and PLIN4 mRNA was validated by RNA immunoprecipitation (RIP)-quantitative PCR. METTL16-mediated m6A modification of PLIN4 was assessed by Methylated RIP (MeRIP)-quantitative PCR. Transcriptional regulation of METTL16 by SPI1 was examined by chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays.

Results

Integrative analysis identified PLIN4 as a core hub gene. PLIN4 was upregulated in the HepG2 steatosis model (P < 0.001). PLIN4 knockdown alleviated lipid droplet accumulation (P < 0.001), reduced TNF-α and IL-6 secretion (P < 0.01), and decreased ROS levels (P < 0.001) in fructose/oleic acid-treated HepG2 cells. Mechanistically, METTL16 mediated its m6A modification to enhance PLIN4 mRNA stability. Furthermore, SPI1 was found to transcriptionally activate METTL16 by binding to its promoter (P < 0.001). PLIN4 re-expression partially reversed the protective effects of SPI1 knockdown on lipid accumulation (P = 0.01), inflammation (P < 0.05), and oxidative stress (P < 0.001).

Conclusion

This study identifies the SPI1/METTL16/PLIN4 axis as a potential regulatory mechanism contributing to in vitro steatosis, inflammation, and oxidative stress in steatotic HepG2 cells.

View source

Similar papers

Oct 2026

Multi-omics integration reveals the CTSK-cholesterol metabolic axis and the cholesterol-RORA/LDLR paracrine axis in SPP1+ macrophages as mediators of 6PPD-quinone-induced idiopathic pulmonary fibrosis.

OBJECTIVE This study aimed to screen and identify potential biomarkers linking 6PPD-quinone (6PPD-Q) exposure to idiopathic pulmonary fibrosis (IPF), generating a mechanistic hypothesis for future experimental investigation and therapeutic development. METHODS 6PPD-Q-related genes and IPF-associated genes were obtain...

Qi-Xuan Wang, Yi-Ting Wu, Peng-Rui Du et al. · 0 citations
Open access Sep 2026

Multi-omics and machine learning-driven identification of PTM-related potential biomarkers and therapeutic insights in MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) is biologically heterogeneous and lacks sufficiently validated molecular biomarkers for disease characterization. Post-translational modification (PTM)-related genes may link metabolic stress to lipid dysregulation and inflammation, but their relevance...

Qing-Rong Yao, Xuan-Chong Zhong, Jia-Wei Chen et al. · 0 citations
Open access Aug 2026

Integrative Multi-omics and Machine Learning Reveal the Therapeutic Mechanisms of Juanyu-Xiaozhi Formula in Metabolic Dysfunction-associated Steatotic Liver Disease and Hepatic Fibrosis via the AP-1/PPARγ/SCD1 Axis

Background and Aims Despite the surging global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and related liver fibrosis, effective treatments remain limited. While the traditional Chinese medicine Juanyu-Xiaozhi Formula (JYXZF) is used against MASLD, its bioactive components and mechani...

Zhi-Qiang Jin, Yi Huang, Cheng Zeng et al. · 0 citations
Aug 2026

Identification of Lactate-related Biomarkers in Non-alcoholic Fatty Liver Disease.

These findings bridge the gap between metabolic lipotoxicity and epigenetic regulation, suggesting that lactylation acts as a critical driver in NAFLD pathogenesis.

Qing-Xuan He, Xu Wang, Peng-Fei Wang et al. · 0 citations
Open access Aug 2026

Lipid Metabolism-related lncRNA Model Identifies AC026412.3 as a Driver of Fatty Acid β-oxidation in Hepatocellular Carcinoma

This study establishes a robust LRL-based prognostic model and identifies AC026412.3 as a key regulator of lipid metabolic reprogramming via the SLC22A5–fatty acid β-oxidation axis, highlighting its potential as a biomarker and therapeutic target in HCC.

Li-Xin Liu, Yu-Hao Fan, Hao Zou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.